Clinical data | |
---|---|
Trade names | Qulipta, Aquipta |
Other names | AGN-241689, MK-8031 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621052 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C29H23F6N5O3 |
Molar mass | 603.525 g·mol−1 |
3D model (JSmol) | |
| |
|
Atogepant, sold under the brand name Qulipta among others, is a medication used to prevent migraines.[4][5] It is a gepant, an orally active calcitonin gene-related peptide receptor antagonist.[4][7]
The most common side effects include nausea (feeling sick), constipation, tiredness, somnolence (sleepiness), decreased appetite, and decreased weight.[5]
Atogepant was approved for medical use in the United States in September 2021,[4][8] and in the European Union in August 2023.[5][9]
Atogepant is indicated for the preventive treatment of episodic migraine in adults.[4][5]
In the European Union, atogepant (Aquipta) is indicated for prophylaxis (prevention) of migraine in adults who have at least four migraine days per month.[5]
The benefits and side effects of atogepant were evaluated in two clinical trials of 1,562 participants with a history of migraine headaches occurring on 4 to 14 days per month.[10] The two trials to show the benefits were designed similarly.[10] Trials 1 and 2 assigned participants to one of several doses of atogepant or placebo daily for three months.[10] Neither the participants nor the health care providers knew which treatment was being given until after the trial was completed.[10] The benefit of atogepant was assessed based on the change from baseline in the number of migraine days per month to the last month of the three-month treatment period, comparing participants in the atogepant and placebo groups.[10] The trials were conducted at over 100 sites in the United States.[10] The safety of atogepant was evaluated in 1,958 participants with migraine who received at least one dose of atogepant; therefore, the number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety.[10]
A study found that atogepant reduced the number of migraine days over twelve weeks.[11]